New Study: Less Invasive GERD Treatment May Work as Well as Standard Surgery, With Fewer Side Effects

Millions of Americans who suffer from chronic heartburn and acid reflux may soon have a new, less intimidating treatment option. A recent study presented at a major medical conference suggests that a minimally invasive procedure for gastroesophageal reflux disease (GERD) can provide relief similar to the current gold-standard surgery—but with a significantly lower risk of trouble swallowing afterward.

For the estimated 76 million people in the United States living with GERD, this news offers hope. Many of these individuals rely on daily medications that only mask symptoms, while fewer than half a percent ever undergo surgery due to fear of complications. This new approach, called transoral incisionless fundoplication (cTIF), could change that.

What Is GERD and Why Does It Matter?

Gastroesophageal reflux disease, commonly called GERD, occurs when the muscular valve at the bottom of the esophagus—the tube connecting your mouth to your stomach—does not close properly. This allows stomach acid to splash back up into the esophagus, causing burning chest pain (heartburn), regurgitation, and sometimes trouble swallowing.

Over time, untreated GERD can damage the lining of the esophagus, leading to more serious conditions like esophagitis (inflammation), strictures (narrowing), or even Barrett’s esophagus, a precancerous condition. Beyond physical discomfort, GERD can disrupt sleep, limit what you can eat, and reduce overall quality of life.

Many people manage their symptoms with medications called proton pump inhibitors (PPIs), which include popular brands like omeprazole (Prilosec) and esomeprazole (Nexium). According to the study’s lead researcher, Dr. Barham K. Abu Dayyeh of Cedars Sinai Medical Center in Los Angeles, about 20 million Americans take these drugs daily. However, PPIs only reduce stomach acid production. They do not fix the underlying problem—a weak or damaged anti-reflux barrier. As a result, millions of people still experience breakthrough symptoms while taking PPIs, and they may also face side effects from long-term use, including nutrient deficiencies and increased infection risk.

The Gold Standard: Laparoscopic Nissen Fundoplication (LNF)

For decades, the most effective surgical treatment for GERD has been a procedure called laparoscopic Nissen fundoplication, or LNF. During LNF, a surgeon makes small incisions in the abdomen and wraps the top of the stomach around the lower esophagus to tighten the valve. This creates a stronger barrier against acid reflux.

While LNF works well for many patients, it has significant drawbacks. The surgery is technically challenging, requires general anesthesia, and can lead to side effects such as dysphagia (difficulty swallowing), gas bloating, and the inability to burp or vomit normally. Because of these issues, only about 30,000 people—less than 0.5% of all GERD patients—choose to undergo this surgery each year.

The New Option: Transoral Incisionless Fundoplication (cTIF)

The cTIF procedure is a “hybrid” approach that combines two techniques. First, surgeons repair any hiatal hernia (a condition where part of the stomach pushes up through the diaphragm) using small laparoscopic incisions. Then, they use an endoscope—a flexible tube with a camera—inserted through the mouth to reconstruct the anti-reflux valve from the inside.

Dr. Abu Dayyeh describes cTIF as a “novel, less invasive hybrid approach” that offers “a collaborative, minimally invasive option that can expand access to effective treatment for GERD.” Because it does not require large incisions or major cutting, patients may recover faster and experience fewer side effects.

What the Study Found

The research was a prospective randomized trial, meaning patients were randomly assigned to receive either cTIF or LNF. It involved 164 patients across seven U.S. medical centers, though only 132 actually underwent the procedures (64 in the cTIF group and 68 in the LNF group). Participants were about 55 years old on average, with an average body mass index (BMI) of 28.4, which falls in the overweight range.

At the start of the study, both groups had similar levels of acid exposure, symptom severity, and overall health. The researchers measured outcomes using several standard tools, including the GERD Health-Related Quality of Life (HRQL) questionnaire, which tracks how much reflux symptoms affect daily living.

Key findings at 6 months:

• GERD-HRQL scores improved by 27.4 points in the cTIF group and 26.9 points in the LNF group—almost identical.
• The adjusted difference between the groups was only 2.04 points, well below the 4.9-point threshold that researchers set to prove non-inferiority (meaning cTIF is not worse than LNF).

Key findings at 12 months:

• GERD-HRQL scores improved by 29.6 points with cTIF and 27.2 points with LNF.
• Other measures, including the Daily Burden of Reflux scores and the Gastrointestinal Quality of Life Index, showed similar improvements in both groups for symptoms, physical function, and social well-being.

The biggest difference: swallowing problems

• At 6 months, 32.3% of LNF patients reported new or worsening difficulty swallowing, compared to only 2.6% of cTIF patients—a highly significant difference.
• At 12 months, 28.6% of LNF patients still had dysphagia, versus just 5.7% in the cTIF group.

Bloating scores also improved more in the cTIF group (3.2 points) than the LNF group (2.3 points), though this difference was not statistically significant.

Safety and complications:

• Serious adverse events were rare and similar: 2.9% with cTIF and 1.6% with LNF.
• The rate of needing a repeat procedure within 90 days was almost identical: 1.5% for cTIF and 1.6% for LNF.

What Experts Say

Dr. Neena Mohan, director of Barrett’s Esophagus and Esophageal Research at Temple Health in Philadelphia, was not involved in the study but commented on its implications. She told MedPage Today that “having more options for GERD management is beneficial for patient care.” However, she emphasized that longer-term studies are needed to see if the advantages of cTIF—especially reduced dysphagia and bloating—hold up over time.

Dr. Mohan also noted that “patient selection and operator experience are important to consider when selecting procedural or surgical options.” In other words, not every patient is a good candidate for cTIF, and the skill of the doctor performing the procedure matters a great deal.

Important Caveats to Keep in Mind

Dr. Abu Dayyeh pointed out that this study focused on patients with smaller hiatal hernias—specifically those 5 centimeters or less in size. People with larger hernias were not included, so the results may not apply to them.

He also stressed that “this does not replace reflux surgery, but adds a validated less invasive option with sustained outcome that can expand access to effective GERD interventions.” In plain language: cTIF is not a substitute for LNF in all cases, but it provides a valuable alternative for the right patients.

Practical Takeaways for Readers

If you or someone you know struggles with GERD, here are some key points to consider:

– Medication is not a cure. PPIs reduce acid but do not fix the valve that causes reflux. Many people still have symptoms or face long-term side effects.

• Surgery is underused. Fear of complications and side effects keeps millions from seeking surgical help. cTIF may reduce that fear.
• cTIF is not for everyone. It appears most suitable for patients with small hiatal hernias. Talk to a gastroenterologist or surgeon to see if you qualify.
• Ask about operator experience. Like any specialized procedure, results depend on how many times the doctor has performed it.
• Lifestyle changes still matter. Even after successful treatment, maintaining a healthy weight, avoiding trigger foods, and not eating late at night can help prevent recurrence.

The Bottom Line

This study offers real hope for the millions of Americans living with GERD who are dissatisfied with daily pills and hesitant about major surgery. The cTIF procedure appears to provide similar symptom relief and quality-of-life improvements as the gold-standard LNF surgery, but with a much lower chance of difficulty swallowing. While more research is needed to confirm long-term results, this less invasive option could soon become a mainstream treatment—making effective GERD care accessible to far more people than ever before.

As always, if you have GERD symptoms, talk to your doctor about all your options. What works for one person may not work for another, but now there is one more tool in the toolbox.

Source: MedPage Today